These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 12682252)
1. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252 [TBL] [Abstract][Full Text] [Related]
2. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710 [TBL] [Abstract][Full Text] [Related]
3. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260 [TBL] [Abstract][Full Text] [Related]
4. Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains. Spreu J; Stehle T; Steinle A J Immunol; 2006 Sep; 177(5):3143-9. PubMed ID: 16920952 [TBL] [Abstract][Full Text] [Related]
5. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848 [TBL] [Abstract][Full Text] [Related]
6. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445 [TBL] [Abstract][Full Text] [Related]
7. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Sutherland CL; Chalupny NJ; Cosman D Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139 [TBL] [Abstract][Full Text] [Related]
8. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands. Müller S; Zocher G; Steinle A; Stehle T PLoS Pathog; 2010 Jan; 6(1):e1000723. PubMed ID: 20090832 [TBL] [Abstract][Full Text] [Related]
9. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960 [TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Chalupny NJ; Rein-Weston A; Dosch S; Cosman D Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166 [TBL] [Abstract][Full Text] [Related]
11. The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope. Valés-Gómez M; Winterhalter A; Roda-Navarro P; Zimmermann A; Boyle L; Hengel H; Brooks A; Reyburn HT Cell Microbiol; 2006 Apr; 8(4):581-90. PubMed ID: 16548884 [TBL] [Abstract][Full Text] [Related]
12. NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. Krmpotic A; Hasan M; Loewendorf A; Saulig T; Halenius A; Lenac T; Polic B; Bubic I; Kriegeskorte A; Pernjak-Pugel E; Messerle M; Hengel H; Busch DH; Koszinowski UH; Jonjic S J Exp Med; 2005 Jan; 201(2):211-20. PubMed ID: 15642742 [TBL] [Abstract][Full Text] [Related]
13. Allelic MHC class I chain related B (MICB) molecules affect the binding to the human cytomegalovirus (HCMV) unique long 16 (UL16) protein: implications for immune surveillance. Klumkrathok K; Jumnainsong A; Leelayuwat C J Microbiol; 2013 Apr; 51(2):241-6. PubMed ID: 23625227 [TBL] [Abstract][Full Text] [Related]
14. Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells. Valés-Gómez M; Browne H; Reyburn HT BMC Immunol; 2003 Mar; 4():4. PubMed ID: 12694635 [TBL] [Abstract][Full Text] [Related]
15. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667 [TBL] [Abstract][Full Text] [Related]
16. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909 [TBL] [Abstract][Full Text] [Related]
17. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531 [TBL] [Abstract][Full Text] [Related]
18. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Song H; Kim J; Cosman D; Choi I Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603 [TBL] [Abstract][Full Text] [Related]
19. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. Fielding CA; Aicheler R; Stanton RJ; Wang EC; Han S; Seirafian S; Davies J; McSharry BP; Weekes MP; Antrobus PR; Prod'homme V; Blanchet FP; Sugrue D; Cuff S; Roberts D; Davison AJ; Lehner PJ; Wilkinson GW; Tomasec P PLoS Pathog; 2014 May; 10(5):e1004058. PubMed ID: 24787765 [TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]